



Corporate

Lonza

EUROPEAN COMMISSION
Call for tenders Ref. SANTE/2020/C3/054

Lonza Ltd
Muenchensteinerstrasse 38
CH-4002 Basel
Switzerland
+41 61 (10)(2e)
+41 61 (10)(2e) lonza.com

Basel, 1 September 2020

We, having the legal capacity required to act on behalf of the company LONZA AG ("LONZA") hereby confirm that our company has entered into a Strategic Collaboration Agreement to enable larger scale manufacture of ModernaTX, Inc's ("MODERNA") mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2). LONZA and its affiliates have also entered into binding Statement of Works under which manufacturing sites for the mRNA vaccine are being established in Visp, Switzerland and Portsmouth, USA.

We further refer in this respect to the news release published on May, 1, 2020 (<https://www.lonza.com/news/2020-05-01-04-50>).

Lonza confirms its agreements to participate as a manufacturing subcontractor in the offer of MODERNA for the Call for tenders SANTE/2020/C3/054 – for the development, production, priority-purchasing options and supply of COVID-19 Vaccines for EU Member States under the terms of its agreements with MODERNA, as elaborated in line with the Tender Specifications.

In the event that the tender of the aforementioned tenderer is successful, LONZA confirms that it will make available the resources necessary for the performance of its manufacturing agreements with MODERNA and to carry out the services that will be subcontracted to it in compliance with the terms of its agreement with MODERNA.

It further declares that it is not aware of conflicting interests which may negatively affect the contract performance and that it will comply with the terms and conditions set forth in its agreement with MODERNA, in particular the contractual provisions related to checks and audits.

Lonza AG

(10)(2e)

(10)(2e)